This page is part of the 國家級人體生物資料庫整合平台共同資料模式實作指引(NBCT Common Data Model IG) (v0.1.0: Releases) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: SSF2 白血病-白血病分子生物學檢查的評估代碼系統 - XML Representation

Active as of 2024-08-01

Raw xml | Download

<CodeSystem xmlns="http://hl7.org/fhir">
  <id value="ssf-2-leukemia-codesystem"/>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: CodeSystem ssf-2-leukemia-codesystem</b></p><a name="ssf-2-leukemia-codesystem"> </a><a name="hcssf-2-leukemia-codesystem"> </a><a name="ssf-2-leukemia-codesystem-en-US"> </a><p>This case-sensitive code system <code>https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem</code> defines the following codes:</p><table class="codes"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style="white-space:nowrap">000<a name="ssf-2-leukemia-codesystem-000"> </a></td><td>正常</td></tr><tr><td style="white-space:nowrap">001<a name="ssf-2-leukemia-codesystem-001"> </a></td><td>AML with RUNX1-RUNX1T1</td></tr><tr><td style="white-space:nowrap">002<a name="ssf-2-leukemia-codesystem-002"> </a></td><td>AML with CBFB-MYH11</td></tr><tr><td style="white-space:nowrap">003<a name="ssf-2-leukemia-codesystem-003"> </a></td><td>Acute promyelocytic leukemia with PML-RARA</td></tr><tr><td style="white-space:nowrap">004<a name="ssf-2-leukemia-codesystem-004"> </a></td><td>AML with KMT2A-MLLT3</td></tr><tr><td style="white-space:nowrap">005<a name="ssf-2-leukemia-codesystem-005"> </a></td><td>AML with DEK-NUP214</td></tr><tr><td style="white-space:nowrap">006<a name="ssf-2-leukemia-codesystem-006"> </a></td><td>AML with GATA2, MECOM</td></tr><tr><td style="white-space:nowrap">007<a name="ssf-2-leukemia-codesystem-007"> </a></td><td>AML(megakaryoblastic) with RBM15-MKL1</td></tr><tr><td style="white-space:nowrap">008<a name="ssf-2-leukemia-codesystem-008"> </a></td><td>AML with mutated NPM1</td></tr><tr><td style="white-space:nowrap">009<a name="ssf-2-leukemia-codesystem-009"> </a></td><td>AML with biallelic mutation of CEBPA</td></tr><tr><td style="white-space:nowrap">010<a name="ssf-2-leukemia-codesystem-010"> </a></td><td>AML with mutated FLT3/ITD</td></tr><tr><td style="white-space:nowrap">011<a name="ssf-2-leukemia-codesystem-011"> </a></td><td>AML with mutated FLT3/TKD</td></tr><tr><td style="white-space:nowrap">012<a name="ssf-2-leukemia-codesystem-012"> </a></td><td>AML with MLL-PTD (partial tandem duplication)</td></tr><tr><td style="white-space:nowrap">013<a name="ssf-2-leukemia-codesystem-013"> </a></td><td>AML with BCR-ABL1</td></tr><tr><td style="white-space:nowrap">021<a name="ssf-2-leukemia-codesystem-021"> </a></td><td>B lymphoblastic leukemia/lymphoma with BCR-ABL1</td></tr><tr><td style="white-space:nowrap">022<a name="ssf-2-leukemia-codesystem-022"> </a></td><td>B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged</td></tr><tr><td style="white-space:nowrap">023<a name="ssf-2-leukemia-codesystem-023"> </a></td><td>B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1)</td></tr><tr><td style="white-space:nowrap">024<a name="ssf-2-leukemia-codesystem-024"> </a></td><td>B-lymphoblastic leukemia/lymphoma with IGH/IL3</td></tr><tr><td style="white-space:nowrap">025<a name="ssf-2-leukemia-codesystem-025"> </a></td><td>B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1)</td></tr><tr><td style="white-space:nowrap">041<a name="ssf-2-leukemia-codesystem-041"> </a></td><td>Mixed phenotype acute leukemia with BCR-ABL1</td></tr><tr><td style="white-space:nowrap">042<a name="ssf-2-leukemia-codesystem-042"> </a></td><td>Mixed-phenotype acute leukemia with KMT2A-rearranged</td></tr><tr><td style="white-space:nowrap">051<a name="ssf-2-leukemia-codesystem-051"> </a></td><td>Chronic myelogenous leukemia BCR-ABL1 positive</td></tr><tr><td style="white-space:nowrap">052<a name="ssf-2-leukemia-codesystem-052"> </a></td><td>JAK2 V617F mutation</td></tr><tr><td style="white-space:nowrap">053<a name="ssf-2-leukemia-codesystem-053"> </a></td><td>Myeloid and lymphoid neoplasms with PDGFRA rearrangement</td></tr><tr><td style="white-space:nowrap">054<a name="ssf-2-leukemia-codesystem-054"> </a></td><td>Myeloid and lymphoid neoplasms with PDGFRB rearrangement</td></tr><tr><td style="white-space:nowrap">055<a name="ssf-2-leukemia-codesystem-055"> </a></td><td>Myeloid and lymphoid neoplasms with FGFR1 rearrangement</td></tr><tr><td style="white-space:nowrap">090<a name="ssf-2-leukemia-codesystem-090"> </a></td><td>(1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常</td></tr><tr><td style="white-space:nowrap">091<a name="ssf-2-leukemia-codesystem-091"> </a></td><td>同時有兩種(含)以上上述之分子檢驗異常</td></tr><tr><td style="white-space:nowrap">092<a name="ssf-2-leukemia-codesystem-092"> </a></td><td>同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常</td></tr><tr><td style="white-space:nowrap">8XX<a name="ssf-2-leukemia-codesystem-8XX"> </a></td><td>Molecular study after chemotherapy or immunotherapy or target therapy</td></tr><tr><td style="white-space:nowrap">988<a name="ssf-2-leukemia-codesystem-988"> </a></td><td>不適用。(1) ICD-O-3 M-9811-9837 (EXCEPT C42.0, 42.1, 42.4)</td></tr><tr><td style="white-space:nowrap">998<a name="ssf-2-leukemia-codesystem-998"> </a></td><td>有執行分子生物學檢查，但結果無法判斷</td></tr><tr><td style="white-space:nowrap">999<a name="ssf-2-leukemia-codesystem-999"> </a></td><td>(1) 病歷未記載或不詳 (2) 未執行分子生物學檢查</td></tr></table></div>
  </text>
  <url
       value="https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem"/>
  <version value="0.1.0"/>
  <name value="SSF2leukemiaCS"/>
  <title value="SSF2 白血病-白血病分子生物學檢查的評估代碼系統"/>
  <status value="active"/>
  <experimental value="false"/>
  <date value="2024-08-01T15:33:47+08:00"/>
  <publisher value="國家級人體生物資料庫整合平台"/>
  <contact>
    <telecom>
      <system value="url"/>
      <value value="https://ghd.tw/"/>
    </telecom>
  </contact>
  <description
               value="Assessment of molecular studies in leukemia Code System"/>
  <caseSensitive value="true"/>
  <content value="complete"/>
  <count value="33"/>
  <concept>
    <code value="000"/>
    <display value="正常"/>
  </concept>
  <concept>
    <code value="001"/>
    <display value="AML with RUNX1-RUNX1T1"/>
  </concept>
  <concept>
    <code value="002"/>
    <display value="AML with CBFB-MYH11"/>
  </concept>
  <concept>
    <code value="003"/>
    <display value="Acute promyelocytic leukemia with PML-RARA"/>
  </concept>
  <concept>
    <code value="004"/>
    <display value="AML with KMT2A-MLLT3"/>
  </concept>
  <concept>
    <code value="005"/>
    <display value="AML with DEK-NUP214"/>
  </concept>
  <concept>
    <code value="006"/>
    <display value="AML with GATA2, MECOM"/>
  </concept>
  <concept>
    <code value="007"/>
    <display value="AML(megakaryoblastic) with RBM15-MKL1"/>
  </concept>
  <concept>
    <code value="008"/>
    <display value="AML with mutated NPM1"/>
  </concept>
  <concept>
    <code value="009"/>
    <display value="AML with biallelic mutation of CEBPA"/>
  </concept>
  <concept>
    <code value="010"/>
    <display value="AML with mutated FLT3/ITD"/>
  </concept>
  <concept>
    <code value="011"/>
    <display value="AML with mutated FLT3/TKD"/>
  </concept>
  <concept>
    <code value="012"/>
    <display value="AML with MLL-PTD (partial tandem duplication)"/>
  </concept>
  <concept>
    <code value="013"/>
    <display value="AML with BCR-ABL1"/>
  </concept>
  <concept>
    <code value="021"/>
    <display value="B lymphoblastic leukemia/lymphoma with BCR-ABL1"/>
  </concept>
  <concept>
    <code value="022"/>
    <display value="B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged"/>
  </concept>
  <concept>
    <code value="023"/>
    <display
             value="B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1)"/>
  </concept>
  <concept>
    <code value="024"/>
    <display value="B-lymphoblastic leukemia/lymphoma with IGH/IL3"/>
  </concept>
  <concept>
    <code value="025"/>
    <display
             value="B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1)"/>
  </concept>
  <concept>
    <code value="041"/>
    <display value="Mixed phenotype acute leukemia with BCR-ABL1"/>
  </concept>
  <concept>
    <code value="042"/>
    <display value="Mixed-phenotype acute leukemia with KMT2A-rearranged"/>
  </concept>
  <concept>
    <code value="051"/>
    <display value="Chronic myelogenous leukemia BCR-ABL1 positive"/>
  </concept>
  <concept>
    <code value="052"/>
    <display value="JAK2 V617F mutation"/>
  </concept>
  <concept>
    <code value="053"/>
    <display
             value="Myeloid and lymphoid neoplasms with PDGFRA rearrangement"/>
  </concept>
  <concept>
    <code value="054"/>
    <display
             value="Myeloid and lymphoid neoplasms with PDGFRB rearrangement"/>
  </concept>
  <concept>
    <code value="055"/>
    <display value="Myeloid and lymphoid neoplasms with FGFR1 rearrangement"/>
  </concept>
  <concept>
    <code value="090"/>
    <display
             value="(1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常"/>
  </concept>
  <concept>
    <code value="091"/>
    <display value="同時有兩種(含)以上上述之分子檢驗異常"/>
  </concept>
  <concept>
    <code value="092"/>
    <display
             value="同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常"/>
  </concept>
  <concept>
    <code value="8XX"/>
    <display
             value="Molecular study after chemotherapy or immunotherapy or target therapy"/>
  </concept>
  <concept>
    <code value="988"/>
    <display value="不適用。(1) ICD-O-3 M-9811-9837 (EXCEPT C42.0, 42.1, 42.4)"/>
  </concept>
  <concept>
    <code value="998"/>
    <display value="有執行分子生物學檢查，但結果無法判斷"/>
  </concept>
  <concept>
    <code value="999"/>
    <display value="(1) 病歷未記載或不詳 (2) 未執行分子生物學檢查"/>
  </concept>
</CodeSystem>